ARCHIVES

No Difference in Toxicity Between IMRT and PRT In Medicare Patients

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

FDA Encourages Study Of Gender Differences

August 6, 1993

The NCI director and acting FDA commissioner called for faster approval of cancer drugs in speech to FDA staff.

October 21, 2005

Symposium Planned On Grantmanship

April 20, 1984

Phase II Study Of Pfizer Drug Meets Primary Endpoint

April 24, 2009

DCT Board Committee Recommends Limited Start On In Vitro Screening Program

January 18, 1985

Litton’s Government Contracts Status Under Review

September 6, 1985